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Abstract
Modern  Molecular  Dynamics  force  fields,  such  as  the  CHARMM36  and  GLYCAM06
carbohydrate force fields, are parametrised to reproduce behaviours for specific molecules
under specific conditions in order to be able to predict the behaviour of similar molecular
systems,  where  there  is  often  no  experimental  data.  Coupled  with  the  sheer  number
available,  this  makes  choosing  the  appropriate  force  field  a  formidable  task.  For  this
reason it is important that modern force fields be regularly compared.
Streptococcus pneumoniae is a cause of invasive pneumococcal disease (IPD) such as
pneumonia and meningitis in children under five. While there are over 90 pneumococcal
serotypes  only  a  handful  of  these are  responsible  for  disease.  Immunisation  with  the
conjugate  vaccine  PCV7,  has  markedly  decreased  invasive  pneumoccocal  disease.
Following PCV7 immunisation, incidences of non-vaccine serotypes, especially serotype
19A,  have  increased.  Serotype  19F's  capsular  polysaccharide  differs  from 19A's  at  a
single linkage position. Where 19A possesses an -D-Glcp-(13)--L-Rhap (G13R), 19F
possesses an  -D-Glcp-(12)--L-Rhap  (G12R) linkage. For this reason it was thought
that a 19F conjugate would cross protect against 19A. Unfortunately PCV7 vaccination
appears to have been largely ineffective against 19A disease.
The lack of conformational information for the G12R and G13R disaccharides provided a
good opportunity to compare the CHARMM and GLYCAM force fields. The dynamics of
the G12R and G13R disaccharides were investigated under both CHARMM and GLYCAM.
While we did identify some discrepancies, overall the force fields were in agreement in
predicting a more flexible G12R than the more restricted G13R. While it is possible that
these differences account for the lack of 19F to 19A cross protection, further research is
required.
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Chapter 1: Introduction
The  extreme  flexibility  of  carbohydrates  often  makes  them  difficult  to  characterise
experimentally.  Experimental  techniques  employed  in  this  field  are  nuclear  magnetic
resonance (NMR) spectroscopy and X-ray crystallography.  These techniques introduce
some potential problems. X-ray crystallography involves obtaining a static structure of the
molecule in a crystalline or solid state. Unfortunately, the flexible nature of carbohydrates
means  they often  adopt  a  number  of  conformations  while  in  solution,  as  opposed  to
remaining in a single static conformation. It is difficult to know whether or not the molecule
persists in the crystalline conformation when in solution. On the other hand, while NMR
spectroscopy  does  provide  data  on  the  conformation  of  carbohydrates  in  solution,  it
presents  an  average  of  all  conformations  throughout  the  duration  of  the  NMR
investigation1,2.  Other  investigative  techniques  such  as  electron  microscopy,  neutron
diffraction and infrared spectroscopy also suffer from similar shortcomings2.
Molecular Dynamics (MD) simulates atomic interactions using a force field, a series of
functions based on Newton's equations of motion,  and a set  of  parameters describing
molecular  behaviours  in  systems involving  hundreds  of  thousands  of  atoms.  The  MD
approach allows for analysis of carbohydrates without the need for averages or crystalline
structures.  Instead  the  carbohydrate  can  be  observed  in  a  time-lapse  style  series  of
frames known as a trajectory. The parameter sets are created through consideration of
both quantum mechanics and the above mentioned experimental techniques3. The results
of  MD  investigations  are  also  often  analysed  in  conjunction  with  NMR  or  X-ray
Crystallographic data1,4–6. In light of the origins of MD parameter sets and the credence
given to the results of experimental techniques, MD is better viewed as complementary,
rather than wholly alternative to experimental techniques3.
The quality of the force field is a key determinator of the reliability of molecular simulations.
Unlike protein force fields that have benefited from research as far back as the 1970s7,
carbohydrate MD is relatively new. The GROningen MOlecular Simulation (GROMOS)8,
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CHARMM9 and GLYCAM10 force fields arguably represent  the dominant force fields in
current  day  carbohydrate  research.  The  first  CHARMM  and  GLYCAM  carbohydrate
parameter  sets  were  only  published  in  198811 and  199512 respectively.  Modern
carbohydrate  force  fields  are  still  missing  key parameters  and  still  produce  results  in
disagreement with one another13. It is therefore of crucial importance that modern force
fields be routinely compared in order to not only guide future force field development but to
aid researchers in choosing the appropriate force field for their investigations.
The CHARMM and GLYCAM force fields have similar  aspects in  their  parametrisation
philosophies. While the CHARMM carbohydrate force field focused on development of a
force field  that  is  compatible  with  other  currently utilised force fields,  GLYCAM06 (the
newest  GLYCAM force  field10),  attempted  to  keep  its  parameters  consistent  with  past
AMBER  protein  parameters.  This  would  allow  for  more  efficient  simulation  of
heterogeneous systems. In the case of CHARMM, the same approach used in CHARMM
force fields concerning other biomolecules was utilised in the carbohydrate force field.
Both CHARMM and GLYCAM06 are parametrised primarily for use in aqueous solutions,
with CHARMM non-bonded parameters developed using solute-water interactions and all
simulations under GLYCAM06 taking place using TIP3P water models (CHARMM also
utilises the TIP3P water model as opposed to GROMOS' favouring of the SPC model2,14,15).
Both CHARMM and GLYCAM06 are further characterised by a lack of 1-4 non-bonded
interaction scaling10,16,17. These common elements help to facilitate comparison.
Invasive pneumococcal disease (IPD) is one of the leading threats to young children today,
with nearly 1 million deaths per year in children under 5 years old18. IPD is the result of
infection by the bacteria  Streptococcus pneumoniae (S. pneumoniae).  Depending upon
the nature of the infection, IPD can manifest in a number of ways, arguably the worst being
meningitis, pneumonia and otitis media. IPD is a significant killer of children below the age
of 5, with the majority of these deaths occurring in emerging countries18. In 2000 alone,
just over 800 000 children died as a result of IPD, with 95% of those deaths occurring in
developing African and Asian countries18. Pneumococcal attack rates in individuals that are
HIV  positive  are  40  times  higher  than  those  that  are  seronegative19.  S.  pneumoniae
potentially poses a greater risk to the populations of countries with high HIV incidence
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rates such as South Africa, than in developed countries where less of the population is HIV
positive.
S.  pneumoniae is  a  gram  negative  bacterium  wrapped  in  a  protective  Capsular
polysaccharide (CPS) coating. Polysaccharides are long chain carbohydrates made up of
a number of units termed monosaccharides. Numerous monosaccharides exist each with
a number of stereoisomers. The monosaccharides bind together in a variety of formations
through linkages called glycosidic linkages. All glycosidic linkages have the dihedral angles
(torsion angles defined using four atoms) Φ (H1-C1-O1-Cx) and Ψ (C1-O1-Cx-Hx) (Figure
2.6). Regarded as the major source of carbohydrate flexibility20, these dihedral angles are
a frequent subject of carbohydrate conformation investigations involving the analysis of the
Φ and Ψ angles  in the form of free energy surfaces (FESs) depicted as Ramachandran
style plots21 (a 2D plot  with  Φ,  Ψ values on the X, Y axes respectively and free energy
values depicted using coloured isocontour lines)4,5,22,23. Owing to the need to fully explore
the entire FES sampling techniques like Metadynamics24 are used in addition to standard
MD approaches. Thus far, over 90 pneumococcal serotypes have been identified and this
number continues to grow, with the serotype 6D having been identified as recently as
200918,25.
Even though only a handful  of  the 90+ serotypes are responsible for severe IPD, the
number of problematic serotypes are higher than in most other diseases combated with
vaccines. For this reason, an effective pneumococcal vaccine must contain a high number
of serotypes (have a high valency). With a valency of seven, Pfizer's PCV7 (marketed as
PrevnarTM/PrevenarTM26) was the first pneumococcal conjugate vaccine to be licensed. It
contains the pneumococcal serotypes that, at the time, were responsible for most of the
IPD in the United States. While PCV7's efficacy varied greatly from region to region 27 it has
been very successful, reducing the incidence of IPD significantly, especially with regard to
vaccine serotype IPD28.
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The post PCV7 era has been characterised by the rise of serogroup 19 as one of the
dominant causes of S. pneumoniae infections worldwide. While the serogroup consists of
serotypes 19A,  19B,  19C and 19F,,  serotypes  19A and 19F are  the  major  causes of
disease29.
19A: [4)--D-ManpNAc-(14)--D-Glcp-(13)--L-Rhap-1-P]
19F: [4)--D-ManpNAc-(14)--D-Glcp-(12)--L-Rhap-1-P]
The CPSs of 19A and 19F consist of  trisaccharide repeating units.  The only structural
difference  between  these  repeating  units  occurs  in  the  bold  portion  of  the  structures
above. 19A has a 3-linked glycosidic bond between the glucose and rhamnose residues
while 19F possesses a 2-linked glycosidic bond30,31.
The stability of 19F meant it was included in the vaccine over 19A. It was believed at the
time  that  with  only  a  single  difference  between  their  CPSs,  19F  could  provide  cross
protection for 19A.  Cross protection means that a vaccine containing just one serotype
might  illicit  antibodies  capable  of  fending  off  multiple  serotypes.  Unfortunately  despite
some promising research32,33,  the post-PCV7 era has been characterised with a rise in
non-vaccine serotype prevalence, especially 19A34–37. This rise is now attributed to non-
vaccine serotype replacement35.  The serotype replacement created the need for newer
vaccines,  PCV10  (marketed  by  GlaxoSmithKline  (GSK)  as  SynflorixTM26)  and  PCV13
(marketed by Pfizer as Prevnar13TM/Prevenar13TM26)28,34,37,38. While PCV13 contains a 19A
conjugate, PCV10 does not26.
The decision of which conjugates to include in a vaccine ideally occurs on the basis of a
comprehensive understanding of the 3D structure of each serotype and how the human
immune system responds to each. There is currently little information, both experimental
and computational, regarding the dynamics of 19A and 19F CPSs.
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1.1. Problem Statement
While protein force fields have in the past been routinely examined39–41, carbohydrate force
fields  are  reviewed  less  frequently.  Further,  comparisons  of  the  newer  carbohydrate-
specifc  force  fields,  such  as  GLYCAM06,  in  their  application  to  disaccharides,  are
exceedingly rare.  Over  the years comparisons between both the current  and previous
generations of CHARMM and GLYCAM force fields have been undertaken with  varied
degrees of conformity in the results13,42,43. One must keep in mind that most force fields are
parametrised to reproduce specific molecular behaviours in specific environments given a
sample of molecules. The aim is to predict the behaviours of similar molecular systems for
which there are often little to no experimental data42. There are a variety of force fields to
choose  from  making  the  choice  of  the  optimum  force  field  difficult,  especially  for
inexperienced users. Choosing the optimum force field for the task at hand is however
extremely important.  This  makes  ongoing  comparisons  between  these  dominant  force
fields crucial.
Little is known about the favoured conformations of 19A and 19F CPSs. There have been
experimental  investigations performed but  to  date30,31,44 only a couple of  computational
investigations have been undertaken4,45. This provides the perfect opportunity to perform a
comparison of leading carbohydrate-specific force fields while obtaining valuable data on
the conformational dynamics of the 19A and 19F CPSs.
1.2. Aims
The aims of this work are twofold: To compare and contrast the results produced by the 
CHARMM and GLYCAM force fields. This will add to the knowledge of force field 
behaviour under a variety of conditions and help future molecular dynamics users to better
select the optimum force field for their needs.; To perform a molecular dynamics structural 
investigation of serotype 19A and 19F in order to better understand the structural 
relationships of these serotypes.
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1.3. Research Questions
1. How does the choice of force field affect the calculated conformations of the
αDGlup-αLRhap disaccharides? In the past CHARMM and GLYCAM have been
compared in disaccharide conformation investigations. The CHARMM parameters
were  demonstrated  to  produce  dissimilar  results  to  those  of  GLYCAM13.  What
impact does the utilisation of a different force field have on the modelling of the
disaccharide conformations?
2. What effect does the 19A and 19F trisaccharide structural difference have on
the conformation of the  αDGlup-αLRhap disaccharide? The PCV7 conjugate
vaccine did not include a 19A serotype conjugate as it was believed that 19A and
19F  CPSs  were  structurally  similar  enough  that  an  adequate  degree  of  cross
protection could be obtained through a single serotype conjugate. The subsequent
increase in 19A prevalence has been attributed to a lack of cross protection and
subsequent non-vaccine serotype replacement35. It would appear that the serotypes
are not structurally similar enough to allow for cross protection, but how dissimilar
are they?
1.4. Approach
To facilitate a force field comparison and identify potential changes between G12R and
G13R, this study begins with computational analysis of the 19A and 19F αDGlup-αLRhap
disaccharides'  glycosidic  linkages (G13R and G12R respectively).  The simulations  are
performed under  both  the  CHARMM and  GLYCAM force  fields.  As  an  initial  point  of
investigation  and  due  to  time  constraints  involved  in  solution  simulations  with  long
durations,  all  simulations  are  performed  in  a  vacuum.  Both  standard  MD simulations
(unbiased) and simulations employing the Metadynamics sampling method (biased) are
undertaken.  The  biased  simulations  utilise  the  Φ and  Ψ  glycosidic  torsion  angles  as
collective  variables to  generate  FESs  in  the  form  of  Ramachandran  style  plots.  The
unbiased simulations are used to create scatter plots to better understand which  energy
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wells are visited and the transition paths between those wells in both disaccharides under
both force fields.
Oligosaccharide  chains,  termed  oligosaccharide  extensions,  matching  the  residue
sequences  of  19A and  19F  are  created.  In  order  to  construct  the  oligosaccharide
extensions,  in  addition  to  the  G12R  and  G13R  simulations  the  βDManpNAc-αDGlcp
linkage  (M14G)  common to  both  serotypes  is  also  simulated.  A lack  of  availability  of
ManNAc CHARMM parameters means the M14G disaccharide is simulated using only the
GLYCAM  force  field. The  minima  obtained  from  the  disaccharide  FESs  are  used  to
construct oligosaccharide extensions consisting of chains of six 19A or 19F trisaccharide
repeating  units.  The  lack  of  viable  phosphate  parameters  at  the  time  for  both  the
CHARMM and GLYCAM force fields means that these extensions are not necessarily true
representations of 19A and 19F CPSs. They do however highlight the potential impact the
choice of force field, as well as the single G12R and G13R structural difference, could
have on CPS conformations.
As  a  further  comparison  point  between  the  disaccharides  and  the  force  fields,  the
behaviour of glucose's primary alcohol group is analysed. The conformation of the primary
alcohol group is defined through the ω torsion angle. The most favourable conformations
throughout all MD (unbiased) and Metadynamics (biased) simulations are identified in both
disaccharides under  both  force  fields.  The primary alcohol  group in  unbiased isolated
glucose will  be similarly analysed to determine what effect, if any, the presence of the
rhamnose residue has on favourable ω angles.
1.5. Thesis Overview
Chapter 2 introduces the biochemistry and methods of classification of carbohydrates. The
relationships between  carbohydrates and immunity as well  as the history of  conjugate
vaccine development are also discussed.
Chapter  3 provides background information on  the  various  aspects  of  the  molecular
dynamics methodologies employed in the study. General molecular dynamics principles
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are  discussed,  as  well  as  the  basics  of  the  Metadynamics  sampling  method.  Brief
development histories of the CHARMM and GLYCAM force fields are also included.
Chapter 4 introduces the molecular structure of serotype 19A and 19F CPS repeating units
and how those structures fit into the problem of non-vaccine serotype replacement. Past
research into these serotypes is also considered.
Chapter  5 details  the  methodology of  the  project,  addressing  hardware  and  software
utilised,  disaccharide  naming  designations,  methods  for  oligosaccharide  extensions,
molecular dynamics simulation settings of importance and in-house software applications
developed and utilised throughout the duration of this study.
Chapter  6 presents the results and discusses their implications. FESs produced under
CHARMM and GLYCAM forcefields for both G12R and G13R are analysed and compared.
The structure of the oligosaccharide extensions are compared and contrasted by force
field  and  glycosidic  linkage.  The  behaviour  of  the  primary  alcohol  group  will  also  be
investigated.
Chapter  7 reviews the findings in terms of suggested future work to be performed. The
need for new force field parameters and the inclusion of additional force fields for future
comparisons are identified amongst other avenues of potential interest.
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Chapter 2: Carbohydrates & Conjugate 
Vaccines
2.1. Carbohydrate Chemistry and Classification
Carbohydrates are so named because many of them can be described by the formula
(CH2O)n and are thus hydrates of carbon. This  simplistic view is not strictly accurate as
many carbohydrates  contain other components such as amine, sulphate and phosphate
groups.
Arguably the most ubiquitous of all biomolecules, carbohydrates are involved in a large
number of organic systems. Some bacteria coat themselves in carbohydrates in an effort
to evade the human immune system. So effective is this strategy that humanity has had to
embrace  a  regime  of  childhood  vaccinations  in  an  attempt  to  control  many  of  these
carbohydrate shielded pathogens46.  Through photosynthesis  plants store energy in  the
form of starch or cellulose. Considering that the starch contained in foods such as rice,
wheat  and  potatoes  forms  the  basis  of  most  humans'  diets,  the  central  role  of
carbohydrates  is  self  evident.  Through  oxidative  metabolism,  both  plants  and  animals
make use of carbohydrates as their primary energy source. Carbohydrates are a crucial
component of both DNA and RNA in the form of deoxyribose and ribose, The carbohydrate
chitin is a key structural component making up the exoskeletons of arthropods, beaks and
gladii  of  cephalopods,  cell  walls of  fungi  and  radulae of molluscs.  In addition to these
structural  roles,  carbohydrates are also found as components in  many glycolipids and
glycoproteins involved in a wide range of processes from molecular recognition and cell
signalling, to protein stabilisation and cryoprotection. 22,47–49
2.1.1. Monosaccharides
Monosaccharides are both the simplest form of carbohydrate and the basic building block
for the more complex carbohydrates.  As such, monosaccharides are also important for
carbohydrate classification. The number of monosaccharides a carbohydrate consists of is
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used to categorise. A carbohydrate with two monosaccharides is known as a disaccharide,
with three the term trisaccharide is used, between two and twenty the term oligosaccharide
is used and beyond twenty the term polysaccharide is used. Monosaccharides usually
conform to the (CH2O)n formula with n being no smaller than three.
The  distinction  between  D-L  stereoisomers  is  demonstrated  by  monosaccharide
glyceraldehyde.  In  Figure  2.1 we  see  glyceraldehyde's  D-L  stereoisomers,  D-
glyceraldehyde  and  L-glyceraldehyde.  D-L  stereoisomers  are  determined  by  the
orientation of the chiral carbon, in this case C2. When the hydroxyl group (OH) of that
carbon is pointing to the right, that is indicative of the D stereoisomer, while a left-pointing
hydroxyl characterises an L stereoisomer. Where more than one chiral carbon is present
the chiral carbon furthest from the carbonyl group is used. A handful of L-sugars are found
in nature but the D enantiomer is dominant with most biochemical processes configured
for the use of D-sugars. 47
Carbon chains of five or more atoms have the potential to form rings. Rings containing less
than five atoms are sterically strained. Rings containing five (furanose) and six (pyranose)
atoms are common. Although rings of more than 6 atoms do occur in nature, for the most
part they serve only minor roles. 47
Even within the rings themselves there is yet more conformational variation. An example of
this variation can be seen in Figure 2.2. The asymmetrical centre introduced at carbon 1
results in stereoisomers known as α and β anomers. In the α anomer, the hydroxyl group
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Figure 2.1. D-glyceraldehyde (a) and L-glyceraldehyde (b)
on carbon 1 exists below the ring while in the β anomer the hydroxyl group occurs above
the ring. In a process called mutarotation, monosaccharides are able to convert between
their  α  and  β  anomers using an intermediary open chain stage. This  results in purified
anomers approaching an equilibrium mixture in an aqueous solution.
Pyranose rings are not planar, but have a defined pucker, the most common of which is
the 4C1 chair (Figure 2.3). We do not consider other ring puckers in this work, such as the
inverted chair or boat, as they are higher in energy50.
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Figure 2.2. The α (a) and β (b) anomers of glucopyranose
Figure 2.3. α-D-glucopyranose in the 4C1 formation
The behaviour of the dihedral angle of the pyranose's 6-hydroxylmethyl, also known as the
primary alcohol  group, under CHARMM derivative force fields has been the subject of
investigation in the past20. In the case of the primary alcohol the dihedral is defined by
either  O5-C5-C6-O6  (ω)  (Figure  2.6)  or  C4-C5-C6-O6  (ω2).  There  are  typically  three
favourable staggered conformations for a primary alcohol group's dihedral angles. These
three conformations are termed trans, gauche+ (g+) and gauche- (g-). The ω dihedral angle
is 180° in trans, 60° in g+ and -60° in g-. Figure 2.4 below shows the relative positioning of
the atoms involved in the ω dihedral with C4 used for positional reference. 20
2.1.2. Oligosaccharides, Polysaccharides and the Glycosidic Bond
As mentioned previously,  a saccharide chain consisting of two to twenty monomers is
regarded as an oligosaccharide. Beyond twenty monomers the chain is classified as a
polysaccharide.  An  oligosaccharide  consisting  of  two  monomers  is  known  as  a
disaccharide while one with three monomers is termed a trisaccharide.
Monosaccharides  are  capable  of  forming  bonds through the  elimination  of  water  in  a
reaction involving the monosaccharide's anomeric hydroxyl and the hydroxyl group of a
second compound. The resulting ester bond is known as a glycosidic bond. This second
compound could  be any number of  hydroxyl  containing  compounds,  including  another
monosaccharide. 47
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Figure 2.4. Trans, g+ and g- primary alcohol conformations
When  two  monosaccharides  are  bound  together  through  a  glycosidic  linkage  a
disaccharide  is  formed  (Figure  2.5).  With  rigid  ring  structures  the  flexibility  of
carbohydrates comes mainly from these glycosidic linkages so although disaccharides are
relatively simple, they contain many of the same aspects influencing conformation and
flexibility in more complex saccharide chains20.
Depending upon the monosaccharides involved, there is potential for glycosidic bonds to
form between any of the carbons (Figure 2.5 involves a 1-4 bond). Provided the second
monomer's  anomeric  carbon  does  not  take  part  in  glycosidic  bond  formation  new
monomers can be added. In this manner the glycosidic linkage forms the backbone and
branches of saccharide chains.
All glycosidic linkages possess torsion angles. Torsion angles of consistent importance in
carbohydrate investigations are Φ and Ψ (Table 2.1 and Figure 2.6).
Torsion Angle Constituent Atoms
Φ H1-C1-O1-Cx
Ψ C1-O1-Cx-Hx
Table 2.1. The atoms making up the Φ and Ψ glycosidic torsion angles
13
Figure 2.5. Disaccharide exhibiting a glycosidic bond
While pyranose rings possess a certain amount of flexibility, the influence this flexibility has
over  carbohydrate  conformation  is  small.  Of  far  greater  influence  are  the  Φ and  Ψ
glycosidic  torsion  angles,  which  define  the  orientation  of  a  glycosidic  bond  which
determines the conformation of saccharide chains as a whole. It  is for this reason that
investigations into carbohydrate conformations tend to focus on the  Φ and  Ψ glycosidic
torsion angles4,5,22,23 and why analysis of component disaccharides is often regarded as an
ideal initial phase in the investigation of the dynamics of more complex carbohydrates6.
2.2. Carbohydrates and Immunity
2.2.1. Capsular Polysaccharides
Carbohydrates play a key role  in the evasion of  the human immune system by some
bacterial  pathogens.  These  bacteria  form  capsules  consisting  of  polysaccharides  that
cover  the  surface  of  the  bacteria.  Depending  upon  the  source  bacteria,  these  CPSs
typically consist of repeating units of between one and six sugar residues51.
The sugary coating forms a barrier that has been demonstrated to provide cryoprotection
and protection from dessication52,53. Some adopt structures similar to those found in the
human body. With a polysaccharide coating of similar sequence to those found in humans,
the immune system is less likely to recognise the bacteria as foreign51. The capsule also
prevents opsonisation, the binding of antibodies to a pathogen to mark it  for disposal.
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Figure 2.6. Φ,  Ψ and  ω torsion/dihedral angles in maltose (picture adapted from Fadda and Woods3)
Without opsonisation the immune system's complement pathways (a set of proteins that
function together to aid antibodies and phagocytes in the clearing of pathogens) cannot be
initiated and phagocytosis by cells such as macrophages is impeded. There are various
mechanisms by which this occurs: Components that would usually allow for alternative
complement  pathway  activation  are  instead  covered  up  by  the  capsule;  Sialic  acid
contained within some capsules causes preferential binding for certain serum proteins that
inhibit the alternative complement pathway; Some capsules decrease binding affinity for
Factor  B  thereby  stopping  the  complement  cascade  midway54.  Some  bacterial
carbohydrate capsules are so effective that mankind has had to resort to vaccination  to
control those pathogens. 
2.2.2. Conjugate Vaccines
In its simplest sense, production of an effective and safe vaccine involves separation of the
disease  causing  components  of  a  germ,  from  the  components  that  illicit  an  immune
response. Once this is achieved, the components that illicit an immune response can be
administered to induce immunity whilst avoiding the deleterious effects of the germ.
It  has  already been  well  established that  a  comprehensive  immune response  against
bacterial CPSs confers immunity against the associated disease55,56. In vulnerable groups,
such as the very young and the elderly, the immune system's response to most CPSs
progresses in a manner that results in no long term immunological memory. Meaning that
usually when someone below the age of 2 or above the age of 65 is vaccinated using a
pure polysaccharide vaccine, the immunity lasts only a short period of time54. The lack of
lasting protection for vulnerable age groups renders pure polysaccharide vaccines unable
to effectively combat bacteria such as S. pneumoniae alone.
A failure to generate immunological memory upon exposure to a CPS can be sidestepped
by attaching a protein (known as a carrier protein) to the CPS57. The exact mechanisms
behind this approach are not fully known. This same principle however is used in modern
conjugate vaccines. The poor CPS immune response in vulnerable groups is avoided by
making use of the immune responses typically associated with proteins.
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2.3. The Rise of Pneumococcal Conjugate Vaccines
S.  pneumoniae was  first  isolated  in  1880  by  both  Louis  Pasteur  (Paris)  and  George
Sternberg  (New  Orleans)  independent  of  one  another.  In  1886  pneumococcus  was
identified as the primary cause of community-acquired bacterial pneumonia. A year later it
was  unknowingly  observed  that  administering  killed  pneumococci  to  rabbits  conferred
immunity to S. pnuemoniae 19,58. 
Despite these early observations, it  took a threat to the viability of  South Africa's gold
industry three decades later to finally galvanise researchers into serious investigation of
vaccination  against  S.  pneumoniae.  Pneumonia  attacks  in  South  African  mining
compounds were approaching 100 cases per 1000 people with a 25% fatality rate. In 1911
testing  of  a  heat-killed  whole  cell  pneumococcal  vaccine  on miners  living  in  the  mine
compounds began59. The efficacy reported in this trial and the trials that followed remain a
point of contention59.
In the mid to late 1920s the capsules surrounding pneumococcal bacteria were identified
as carbohydrates and their  immunogenicity  was confirmed.  Research began into pure
polysaccharide vaccines, which proved to be rather efficacious, leading to licensing of both
an adult and a paediatric hexavalent vaccine in the 1940s. These licences lapsed soon
after  due  to  lack  of  use  following  introduction  of  antibiotic  treatments  rendering  S.
pneumoniae a controlled issue in the eyes of the public59,60.  The emergence of antibiotic
resistant pneumococci and the identification of key problems such as high mortality rates
in those over 50, renewed interest in prophylaxis. A 14-valent polysaccharide vaccine was
licensed in the United States in 1978 with a 23-valent vaccine following soon after in 1983
59,61,62. Merck's Pneumovax 23 is still in use today containing serotypes 1, 2, 3, 4, 5, 6B, 7F,
8,  9N,  9V,  10A,  11A,  12F,  14,  15B,  17F,  18C,  19F,  19A,  20,  22F,  23F and 33F.  The
serotypes in the Pneumovax 23 vaccine represent 85-90% of the serotypes involved in
IPDs19,63.
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The previously mentioned shortcomings of  polysaccharide  vaccines in  infants  and the
elderly led to the need for the current generation of pneumococcal conjugate vaccines.
The  first  conjugate  vaccine  produced  was  Wyeth's  Prevnar  7  (PCV7)  in  2000.  Until
recently,  PCV7  has  been  the stalwart  conjugate  vaccine  licensed  for  use  against S.
pneumoniae. Containing the majority of disease causing serotypes in the United States at
the time (4, 6B, 9V, 14, 18C, 19F, and 23F),  this vaccine's efficacy varied widely with an
estimated greater than 80% efficacy in North America and Oceania, 40% in Asia and 60%
in Africa and Latin America27,61.  This varied efficacy, along with the occurrence of non-
vaccine serotype replacement35 led to the introduction of the most recent vaccines for S.
pneumoniae, PCV10 and PCV1328,37,64.
Looking  to  the  future,  Merck  has  already  begun  trials  on  a  15  valent  pneumococcal
conjugate vaccine65.
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Chapter 3: Molecular Modelling
3.1. Molecular Dynamics
Molecular Dynamics (MD) involves the use of computers to simulate the movement of
atoms or groups of atoms in a system. MD relies on Newtonian equations of motion. Of
particular importance is Newton's second equation of motion:
Fα=mα aα (1)
In equation 1,  F is the force exerted upon a particular particle (α) while  m and a are the
respective mass and acceleration of the particle. Fα, expressed as a gradient of potential
energy produces the following equation:
Fα=−∇V (2)
In equation 2, V is the system's total potential energy. Molecular modelling typically uses a
pairwise force expression,  where the system's total  potential  comprises of  all  covalent
bonds, angled bonds (pairs of covalent bonds sharing a common atom), dihedral bonds
(atoms separated by precisely three covalent bonds leading to the formation of the torsion
angle  Φ)  and  non-bonded  interactions  (electrostatic  interactions  and  van  der  Waal's
forces). The heart of any modern MD application is the force field. The force field is a set of
parameters that collectively describe the forces experienced by all atoms and the potential
energy of the system. If equations 1 and 2 above are combined the result is the following:
− dV
d rα
=m
d2 rα
d tα
2
(3)
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In equation  3, acceleration has been replaced with atom  α's position (rα) over time (t).
Force experienced by particle  α relates  to  potential  energy changes when in  different
positions. As seen in equation 1, through knowledge of total forces and atomic masses for
a  particular  atom,  acceleration  of  that  atom  can  be  determined.  The  velocity  of  any
particular atom is dependent upon the forces exerted upon that atom by the other atoms
within the system. With these calculations, MD applications are capable of determining the
positions and acceleration of all atoms systemwide over a series of incremental time steps.
This time series of atomic positions is known as a trajectory. A system's trajectory can be
obtained by solving differential equation  3. The wealth of information obtainable from a
system's trajectory makes it one of the most important outputs of an MD simulation.
Use of the force field parameters to calculate the potential is computationally intensive.
Shorter  time  steps  mean  a  higher  degree  of  accuracy  but  greater  computational
requirements. Conversely longer time steps mean less accuracy and lower computational
requirements.
Protein and DNA force fields are well established and have benefited from a long period of
development. Carbohydrate force fields however have not yet reached the same level of
refinement and sophistication. Even some of the dominant carbohydrate force fields have
only  recently  added  parameters  for  complex  side  groups  and  also  some  basic
monosaccharide  units.  CHARMM  for  example  recently  added  sulphates  and
phosphates66 and did not contain parameters for the rhamnose residue until late 2011.
3.2. Carbohydrate Parameter Sets
Section 3.1 above presents examples forming the basis of the functions involved in MD.
The form of the functions utilised differs from one force field to another. The combination of
the form of each of those functions, and the accompanying parameter sets describing
each atom type, define each force field. The development of these parameter sets are
most  often an arduous task  requiring  meticulous attention  to  detail.  While  in  the past
experimental  data  alone  was  sufficient  for  parametrisation,  today  a  combination  of
quantum  mechanical  and  experimental  data  are  utilised3.  The  dominant  force  field
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parameter sets in use today all have a rich history, an understanding of that history can
help one to choose the correct force field for the task and to put the results of the MD
investigation into context.
3.2.1. CHARMM
Maintained currently  by Alex  MacKerell Jr.'s  team from the University of  Maryland, the
CHARMM series of all-atom force fields were originally developed with the modelling of
proteins  and  nucleic  acids  in  mind9.  Over  time  parameter  sets  for  lipids,  DNA,  RNA,
carbohydrates and a handful of other extensions have been added 9. Although the force
field  and  its  accompanying  parameter  sets  were  primarily  produced  for  use  with  the
CHARMM MD application, many other MD programs have been developed or extended to
utilise them.
The CHARMM carbohydrate force field is the most recent addition to the CHARMM force
field series. Parameter set development began with the first CHARMM monosaccharide
parameters published in 198811.  In  1993 Grootenhuis  et al. published a parameter set
entitled “CHEAT”. CHEAT was CHARMM-based and involved mimicry of a molecule in an
aqueous solution through an isolated simulation of that molecule67,68. One of the earliest
true carbohydrate  parameter  sets  for  CHARMM was presented in  1996.  The result  of
stringing  together  ab  initio  calculations  in  small  molecular  systems  such  as  methanol
interacting with water (dubbed “molecular fragments”),  the parameter  set extended the
CHARMM22 force field69.
Further  extensions  served  to  bring  the  evolving  force  field  into  closer  alignment  with
experimental observations. For example Kuttel et al.'s Carbohydrate Solution Force Field
(CSFF) addressed a CHARMM derivative's tendency to favour the trans conformation of
rotametric distributions and frequencies in solution20.
The CHARMM force field's carbohydrate parameter set is continuously being extended.
Some  recent  extensions  include  additional  parameters  for  hexopyranose
monosaccharides  and  their  glycosidic  linkages  16,70 and  more  recently  the  addition  of
phosphate and sulfate parameters66.
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3.2.2. GLYCAM
GLYCAM is  a  series  of  carbohydrate  force fields  produced and maintained by Robert
Woods' research group at the University of Georgia71. GLYCAM was originally designed as
a parameter set dependant on the MD application AMBER10. In the early 1990s, to address
the lack of carbohydrate parameters in AMBER, a series of carbohydrate parameter sets
were  produced using  the  AMBER force  field  as  a base  68,72,73.  Along with  these other
parameter sets, the Woods team presented their own parameter set called GLYCAM_93
for use with the AMBER force field 12.
The  most  recent  leap  forward  is  the  release  of  GLYCAM06.  Unlike  its  predecessors,
GLYCAM06  is  independent  of  AMBER.  The  testing  and  training  involved  around  100
hydrocarbon molecules from a variety of side group categories including alcohols, amides
and ethers along with simple ring structures. If at any point during a torsion rotation an
internal hydrogen bond could be formed, two energy curves would be analysed, with one
curve permitting the hydrogen bond and another disallowing it10 .
3.2.3. GROMOS
The  first  major  GROningen  MOlecular  Simulation  (GROMOS)8 force  field  was
GROMOS8774. This was followed nearly a decade later by GROMOS968.
The  53A6  and  45A4  force  field  parameter  sets  were  produced  in  2004  and  2005
respectively14,15,75. While 53A6 was a general force field and 45A4 was built for use with
carbohydrates, the 45A4 parameter set was incorporated into 53A6 making them near
identical in pure carbohydrate simulations2. These force field parameters have a strong
history, being utilised in numerous investigations6,76–79.
The latest development in the GROMOS carbohydrate force fields is designated 56ACARBO.
Designed for use for hexopyranose based systems, 56ACARBO is a reoptimised version of
the general 53A6 force field. The 56ACARBO parameter set addresses key flaws identified in
the 53A6 parameter set 2.
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3.3. Metadynamics Sampling
To  be  useful,  MD  simulations  should  visit  as  many  energetically  relevant  structural
conformations as possible. MD relies on deterministic systems emulating natural forces to
bring  about  conformational  change.  For  this  reason  MD  simulations  have  limitations.
Relying on natural fluctuations in systemic forces leaves the user with little control over
how quickly and whether or not a system will adopt relevant conformations.
Relying  upon  natural  forces  it  may take  the  system a  long  time  to  visit  the  relevant
conformations, making simulations needlessly time consuming. Another possibility is that
energy wells on the FES may be separated by high energy barriers that are difficult, if not
impossible, to overcome through natural forces. This means that crucial areas of the FES
could remain inadequately sampled or entirely unvisited in a standard MD simulation.
To address these issues, certain MD approaches involve the application of external forces
to a system. This allows the user to simulate situations that might be rare or even entirely
impossible in nature.  These artificial  situations allow users to produce information that
would not be obtainable through physical experimentation. Examples include Umbrella80,
Adaptive Biasing Force81 and Metadynamics sampling techniques24.
First introduced by Laio and Parrinello in 200224, Metadynamics is an enhanced sampling
technique usually employed in MD. Metadynamics produces a representation of the FES
of a system through the allowance of rigidly defined degrees of freedom such as bond
lengths and torsion angles.
The principle behind Metadynamics can be described using the analogy of a blind man
trapped in an empty swimming pool with a bucket containing an infinite supply of sand.
Unable to see or climb, he cannot escape the deep end of the pool. The man begins
pouring sand from the bucket into the bottom of the pool to fill the well of the deep end.
When it is sufficiently filled, he is able to walk along the sand and enter the shallow end's
well. Over time he again fills the shallow well with sand. Continuing in this manner the
blind man eventually fills the entire pool and is able to escape. If he were able to recall
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where every bucket of sand were dropped, he would have an opposite image of the pool's
topography  and  would  therefore  be  able  to  accurately  reconstruct  the  original
topography82.
With Metadynamics, like the sand, a history-dependant biasing force acts to discourage
the system from returning to previously visited conformations. While carbohydrates are
flexible,  and  usually  occupy  a  variety  of  conformations,  they  are  often  separated  by
significant  energy  barriers.  This  makes  Metadynamics  an  invaluable  carbohydrate
conformational analysis tool when analysing Φ and Ψ glycosidic torsion angles. The Kuttel
and Naidoo study83,  for  example,  utilised  a  biasing  force  similar  to  the  Metadynamics
approach in order to overcome significant energy barriers in the maltose FES. While it is
possible that the lower energy barrier could have been overcome given enough time in an
unbiased simulation, it is unlikely that the larger barrier, representing an energy difference
of over 10kcal/mol in vacuo, would have been overcome.
The defined degrees of freedom in Metadynamics are referred to as collective variables
(CVs). The choice of appropriate CVs is essential and the nature of those CVs depends
largely  upon  what  is  being  studied.  Investigations  of  carbohydrates  involving
Metadynamics have utilised numerous CVs including ω primary alcohol dihedral angles84
and  ring pucker coordinates50,85–87.  All  CVs have three fundamental  requirements: First,
CVs  must  collectively  form an  accurate  description  of  the  conformational  transition  of
interest. In other words they must collectively describe the system's initial state, final state
and all relevant intermediary states; Second, the CVs must encompass all variables that
could not otherwise be sampled within the simulation's duration. These otherwise slower
changing variables need to be fully explored before the simulation's end while the faster
changing variables can simply react to the bias-influenced changes in the slower variables;
Finally the number of CVs should be kept low. If too many CVs are defined it means the
space to be explored in order to produce an FES has many dimensions. This will quickly
result in impractical processing times. 88–90
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The bias potential can be calculated from the following equation: 
V G(S , t )=∫
0
t
dt 'ω exp (∑i=1
d (Si(R)−Si (R( t
')))2
2σ i
2 ) (4)
Equation 4 allows one to calculate the bias potential (VG) for the set of CVs (S) at time (t).
The  bold  portion  concerns  the  CVs  of  the  system.  It  originates  from the  equation  5
involving a set of CVs (S), defined as a number of functions (d) of a set of coordinates (R).
S (R)=(S1(R) , ... , Sd(R)) (5)
The  biasing  force  is  the  sum  of  deposited  Gaussian  functions  (a  type  of  function
characterised graphically as a symmetric bell-curve). The characteristics of the Gaussian
are considered in equation 4. While σi is the width of the Gaussian of the ith CV, ω is the
energy rate expressed as follows:
ω=WτG
(6)
where W is the Gaussian height and τG is the duration between deposition of Gaussians.
Metadynamics  algorithms  allow  for  setting  of  the  duration  between  the  addition  of
Gaussian functions,  Gaussian  height  and Gaussian  width in  order  to  strike a balance
between accuracy and computation time. This allows the Metadynamics approach to be
highly flexible.  By changing the characteristics of  the Gaussians, the algorithm can be
made to produce anything from a quick and rough estimate of the FES, to a high duration
simulation resulting in an FES with high granularity.
The  Metadynamics  sampling  technique  provides  an  adaptable  and  reliable  approach
ensuring that every portion of the carbohydrate's FES is adequately explored. With the
ability to identify energy wells that would otherwise have gone undiscovered, it represents
a valuable addition to the MD arsenal.
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Chapter 4: Streptococcus pneumoniae
S.  pneumoniae,  a  gram-positive  encapsulated bacteria,  is  one  of  the  main  causes  of
morbidity and mortality with an estimated 1.6 million deaths per annum27,91. Of those 1.6
million deaths somewhere between 700 000 and 1 million occur in children under 5 years
of age27. IPD includes otitus media, meningitis, bacteraemia and pneumonia92,93. Looking
at these brief figures it is clear that S. pneumoniae represents a significant threat to human
life.
To date over 90 pneumococcal serotypes have been identified with new variants still being
discovered in the wild25,27,91,94–97. Despite this large number of serotypes only a fraction are
responsible for severe IPDs. Of particular concern are serotypes that are highly prevalent,
persist for a long duration, cause IPD and are antibiotic resistant. Against many of these
serotypes humanity's major defence comes from conjugate vaccines administered early in
life.
4.1. Pneumococcal Serotypes 19A and 19F
Pneumococcal serogroup 19 contains serotypes involved in the development of severe
IPDs. Often antibiotic resistant and carried for long durations, members of serogroup 19
can be difficult to treat36,95,98,99. While the serogroup contains serotypes 19A, 19B, 19C and
19F96, serotypes 19F and 19A are of particular interest. In the wake of the roll out of PCV7,
these two serotypes, in particular serotype 19A, rose to become two of the most common
causes of IPD35,100.
Serotype Structure
19F 4)--D-ManpNAc-(14)--D-Glcp-(12)--L-Rhap-1-P
19A 4)--D-ManpNAc-(14)--D-Glcp-(13)--L-Rhap-1-P
Table 4.1. S. pneumoniae serotypes 19A and 19F trisaccharide repeating units
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19A and 19F CPS repeating units are structurally similar (Table 5.1 and Figure 5.2) with
only a single variation in the glycosidic bond between the glucose and rhamnose residues.
In the case of 19A this bond is a 1-3 configuration while in 19F it is substituted with a 1-2
bond30,31,101,102.
There have been a couple of investigations into serotypes 19A and 19F involving use of
computational methods. The first such investigation was conducted in 19924. This work
utilised  the  experimental method  H-NMR and  the  now largely  outdated  computational
approach of simple hard sphere (HSEA)103 and the MM2 force field104. The disaccharides
making up the 19A and 19F trisaccharide repeating units were investigated (Table 4.2).
Using HSEA, the study produced FESs for each of the three disaccharides using Φ and Ψ
dihedral angles. MM2 analysis followed with a search around the MM2 identified minima in
1° intervals for the true minima. This approach allowed for the identification of additional
global and local minima for each disaccharide.
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Figure 4.1. 19F (a) and 19A (b) S. pneumoniae capsular polysaccharide repeating units
Serotype Component Disaccharides
19A
-D-ManpNAc-(14)--D-Glcp
-D-Glcp-(13)--L-Rhap
19F
-D-ManpNAc-(14)--D-Glcp
-D-Glcp-(12)--L-Rhap
Table 4.2. 19A and 19F component disaccharides as investigated by Ciuffreda et al.4
A second MD investigation  into  serogroup 19 involved a synthesised variation  on the
serotype 19F trisaccharide repeating unit45. This synthesised variation, while maintaining
near  conformational  equivalence to  the naturally occurring 19F trisaccharide,  exhibited
higher stability making it potentially useful for inclusion in a vaccine. As with the previous
study,  this  work  did  not  utilise  current  dominant  carbohydrate  force  fields  such  as
CHARMM, GLYCAM and GROMOS, instead utilising Hyperchem's MM+ force field, based
upon the MM2 force field105 used in the Ciuffreda et al study4.
Both studies presented rigid disaccharides consisting of glycosidic linkages with limited Φ
and  Ψ ranges4,45.  Only single wells  of  low energy were observed with  Ciuffreda  et al.
observing some limited additional points of low energy without distinct wells4.
4.1.1. Pneumococcal Non-vaccine Serotype Replacement
PCV7, while undeniably effective, contained only 7 serotypes (4, 6B, 9V, 14, 18C, 19F, and
23F) of the over 90 known pneumococcal serotypes. Prior to the introduction of PCV7,
pneumococcal serotypes 19F and 19A were common. Both were also readily associated
with IPDs. After the widescale introduction of PCV7 19A rose in prevalence until it became
the dominant S. pneumoniae serotype in many areas of the world. This is today identified
as an example of non-vaccine serotype replacement35.
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The change in pneumococcal serotype prevalence figures in the post PCV7 era made it
apparent  that  the  vaccine's  coverage  was  inadequate.  Pfizer  introduced  PCV13 as  a
replacement for PCV7 while GSK introduced its own pneumococcal vaccine, PCV10, all
with differing component serotypes106 (Table 4.3).
Vaccine Serotypes
PCV7 4, 6B, 9V, 14, 18C, 19F, 23F106
PCV10 PCV7 + 1, 5, 7F106
PCV13 PCV10 + 3, 6A, 19A106
Table 4.3. Component serotypes of pneumococcal conjugate vaccines
Even before the introduction of PCV7, whether or not structural similarities between the
CPSs of serotypes 19A and 19F might allow one to cross protect for the other was already
a contentious issue107. The advantage of cross protection is that it reduces the cost of the
vaccine without compromising its protective capabilities. Unfortunately the 19F conjugate
in PCV7 did not provide adequate cross protection for 19A pneumococcal serotypes33.
Today the issue of cross protection between serotypes 19A and 19F remains an issue of
concern as PCV13 contains a 19A conjugate while PCV10 does not. Initial investigations
have  suggested  that  PCV13  induces  immunity  to  serotype  19A108–110.  GSK's  PCV10
however utilises a different method for joining the protein and carbohydrate components of
the conjugate to those seen in Pfizer's PCV7 and PCV13. It has been argued that GSK's
approach could influence cross protection between serotypes 19A and 19F111. There have
also  been  numerous  cost  analysis  investigations  into  the  viability  of  both  PCV10 and
PCV13 in numerous countries with a variety of conclusions being drawn102,106,112.
There is a lack of investigation into PCV10's ability to provide cross protection for 19A as
well  as  persistent  questions  hanging  over  the  issue  of  serotype  19A and  19F  cross
protection. Coupled with the lack of any MD investigations into these serotypes involving
modern dominant carbohydrate force fields such as CHARMM and GLYCAM, the need for
further research is readily apparent.
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Chapter 5: Methodology
5.1. Approach
This  study  made  use  of  the  NAMD  MD  application113,114,  along  with  the  colvars
Metadynamics sampling module,  in the investigation of the Streptococcus pneumoniae
serotype 19A and 19F CPS repeating units.  Of  importance was a comparison of their
behaviour under both the CHARMM and GLYCAM force fields.
In  addition  to  biased  Metadynamics  simulations,  unbiased  simulations  were  also
performed on the G12R and G13R disaccharides as well as glucose under both CHARMM
and GLYCAM. This facilitated glycosidic linkage comparisons and force field comparisons.
These unbiased simulations were performed to observe molecular behaviours in absence
of the Metadynamics biasing forces, reveal potential traversal paths between energy wells
and other such behaviours not easily observed in biased simulations. In particular,  the
glucose residue's primary alcohol group was thought to be involved in interresidue bonding
patterns and so became an area of interest. Glucose was simulated under both force fields
to determine whether or not the behaviour of the primary alcohol group was influenced by
the presence of the rhamnose residue.
Oligosaccharide extensions were created for each of the glycosidic linkages under each of
the force fields. These extensions allowed for observation of the potential impact of not
only the serotype linkage differences but also the relative shifts of the minima across the
CHARMM and GLYCAM force fields.
5.2. Molecular Designations
Due to a lack of adequate parameters in both the GLYCAM and CHARMM forcefields, it
was decided that  the isolation  of  the disaccharide pair  exhibiting the single difference
between  the  19A and  19F  CPSs  would  be  the  main  focus  of  the  investigation.  The
sequences of the component disaccharides were obtained from previous research30,31. The
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designations assigned to each  disaccharide utilised in the investigation can be seen in
Table 5.1.
Serotype Disaccharide Structure Designation
CHARMM GLYCAM
19F -D-Glcp-(12)--L-Rhap G12R_C G12R_G
19A -D-Glcp-(13)--L-Rhap G13R_C G13R_G
Both -D-ManpNAc-(14)--D-Glcp N/A M14G_G
Table 5.1. Disaccharide designations
The structural difference between the 19A and 19F serotype trisaccharide repeating units
is seen in Table 5.1. In the 19A serotype the glycosidic linkage appears in the form of a 1-3
bond while in 19F a 1-2 bond is observed. The 1-2 linkage was designated G12R, while
the 1-3 linkage was designated G13R. The M14G linkage was used in the construction of
oligosaccharide  extensions.  A  lack  of  availability  of  NAc  group  parameters  for  the
CHARMM  force  field  meant  that  the  M14G  disaccharide was  only  simulated  in  the
GLYCAM force field.
The glucose primary alcohol group's O'5-C'5-C'6-O'6  atoms were defined as the ω dihedral
angle(Figure 5.1). This angle was used in all subsequent primary alcohol measurements.
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Figure 5.1. Atoms defining the primary alcohol ω dihedral
5.3. MD Simulation Parameters
In  order  to  validate the biased simulations and extract  representative conformations a
series of unbiased simulations were performed on both the disacchardes of interest and
glucose.  These  simulations  were  performed  in  a  vacuum  following  a  10  000  step
minimisation  phase  with  a  temperature  control  and  equilibration  regime involving  25K
temperature  reassignments  culminating  in  a  maximum  temperature  of  300K  with
simulation durations of 100ns. In order to better smooth the cutoff of electrostatic and van
der Waal's forces, NAMD's switching algorithms were utilised with a cutoff distance of 15Å.
A point of concern does warrant specific mention. When using the default CHARMM force
field in NAMD, the scnb value is not considered (i.e. 1-4 van der Waal's interactions are
not scaled in the CHARMM force field). In a similar fashion to the CHARMM force field,
GLYCAM requires no scaling of the 1-4 van der Waal's interactions. However the GLYCAM
force  field  uses  the  AMBER  file  format,  which  requires  the  use  of  NAMD's  AMBER
parameters  options.  The  use  of  the  AMBER  parameters  option  in  turn  involves  the
consideration of scnb values, which are defaulted to a value of 2. This is done to facilitate
the  requirements  of  traditional  AMBER  force  fields.  As  this  investigation  called  for
equivalence in force field behaviours, 1-4 van der Waal's interaction scaling was prevented
in the GLYCAM force field by using an explicit scnb value of 1.
For complete NAMD configuration file examples see appendix A.
5.4. Metadynamics Simulations
The Metadynamics sampling method was employed to generate accurate FESs for the
disaccharides. The Metadynamics simulations were performed using the M14G, G12R_C,
G12R_G, G13R_C and G13R_G disaccharides. Simulations were run for a duration of
1500ns. While 1500ns is usually an excessive duration for a MD simulation, the extended
duration helped to ensure that the FESs of all disaccharides were fully explored.
31
Glycosidic  Φ and Ψ dihedral  angles were assigned as collective variables. The atoms
used in defining the Φ and Ψ dihedral angles are shown in Table 5.2, with the positioning
of the dihedrals shown in Figure 5.2. A bin width of 2.5° was employed with boundaries of
-180° and 180° resulting in a representative FES allowing for full exploration of all possible
glycosidic dihedral angle values (Appendix B).
Disaccharide Φ Ψ
G12R H'1-C'1-O2-C2 C'1-O2-C2-H2
G13R H'1-C'1-O3-C3 C'1-O3-C3-H3
Table 5.2. Φ and Ψ glycosidic dihedral angle component atoms 
5.5. MD Analysis
Metadynamics sampling involves the use of the colvars module (Appendix B). The NAMD
colvars module outputs the resultant FES in the form of a Potential of Mean Force (PMF)
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Figure 5.2. Φ and Ψ dihedral angles of G12R (left) and G13R (right)
file. This file consists of entries with Φ and Ψ angles along with the associated free energy
value for the system. Using this PMF file, a 2D Ramachandran style FES21 with  Φ,  Ψ
values on the X, Y axes respectively and free energy values depicted using coloured
isocontour lines, was created for G12R_C, G12R_G, G13R_C and G13R_G.
The minima were determined and the corresponding frames of all disaccharides under all
force fields were isolated and converted into trajectories. Analysis and comparison was
then performed using the Visual  Molecular  Dynamics (VMD) application's  Hbonds and
Licorice graphical representation algorithms. A hydrogen bond limit of 3.4Å at an angle of
100° was decided upon.
In order  to better  understand the likely transition paths between the energy wells,  the
lowest  energy  values  for  each  Metadynamics  Ψ bin  were  determined.  This  minimum
energy  path  was  then  visualised  as  a  plot  of  Ψ against  free  energy  values  and  the
differences between the minima and maxima along the path were determined.
Rotametric  frequency figures  were  obtained  to  determine  probability  of  occurrence  of
primary  alcohol  ω  conformations.  These  probability  figures  were  used  to  produce
histograms identifying distinct peaks of high probability. The frames corresponding to those
peaks were isolated allowing for analysis and comparisons across force fields.
5.6. Oligosaccharide Extensions
Using the in-house CarbBuilder software, three alternate oligosaccharide structures were
built  for  both  19F  and  19A  sequences,  to  give  a  total  of  six  molecules.  Each
oligosaccharide  consisted  of  six  trisaccharide  repeating  units.  Minimum  energy
conformations  obtained  from the  G12R,  G13R and  M14G FESs  wre  used  to  set  the
dihedral angles in the oligosaccharides (Table 5.3).
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Extension
Designation Force Field
Minimum Energy
Conformation Linkage
M14G13R_CA6 CHARMM A G13R
M14G13R_GA6 GLYCAM A G13R
M14G12R_CA6 CHARMM A G12R
M14G12R_CB6 CHARMM B G12R
M14G12R_GA6 GLYCAM A G12R
M14G12R_GB6 GLYCAM B G12R
ALL GLYCAM A M14G
ALL Phosphodiester
Table 5.3. Oligosaccharide extension designations and component linkages
The lack  of  NAc group parameters  in  the  CHARMM force field  meant  that  the  global
minimum  of  M14G  under  GLYCAM  was  utilised  for  all  oligosaccharide  extensions.
Similarly, while CHARMM does possess some added phosphate parameters66, both force
fields lack phosphate parameters for the highly flexible anomeric phosphodiester linkages.
This led to the usage of 0° for the phosphodiester torsion angles.
5.7. Software and Hardware
MD simulations were carried out using NAMD113,114 Linux-x86_64 version 2.9. NAMD was
chosen as the MD application because of its ability to utilise multiple force field file formats,
including in particular the CHARMM and AMBER formats. This feature allowed for a force
field comparison within a single MD application thereby eliminating the potential impact of
differences between MD applications.
MD  simulations  were  performed  on  the University  of  Cape  Town  High  Performance
Computing Centre cluster nodes consisting of Intel Xeon 5660s running at 2800MHz. The
cluster operated on Scientific Linux SL release 5.4 (Boron) with the use of the TORQUE
Resource Management application to manage cluster resources.
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The MacKerell group's CHARMM36 all-atom carbohydrate force field (April 2012 version)
was used17. The CHARMM structure files (Protein Data Bank (PDB) and Protein Structure
File (PSF)) were constructed using the In house CARBLOADER_builder.
For this investigation, GLYCAM 06h force field parameters were used10..  The topology,
coordinate and PDB files were constructed using the AMBER/GLYCAM Configurator tool
also known as the Biomolecule Builder, available on the Woods Group's Glycam website71.
The  disaccharides  were  built  by  selecting  the  appropriate  conformational  isomer  and
residue information followed finally with an -OH sequence terminator.
The  Visual  MD  (VMD)  application  version  1.9.1  and  the  accompanying  Tcl  scripting
framework were utilised for  the purposes of  molecular  visualisation and analysis.  This
included  molecular  visualisation,  analysis  of  non-bonded  interactions  and  creation  of
smaller, more manageable trajectories containing only the frames of interest (Appendix D).
Creation of graphical data representations was facilitated via the gnuplot command line
plotting program, version 4.6 patch level 2.
5.8. Streptococcus pneumoniae Analysis Package
In  addition  to  established  applications  such  as  NAMD  and  VMD,  an  in  house  Java
application named the Streptococcus pneumoniae Analysis Package (StrAP) was written
by the author during this investigation. The complete documented StrAP source code has
been made available on GitHub115.
The long simulation durations required by the Metadynamics sampling methods resulted in
unwieldy trajectories of 1.5 million frames. Written in Java, StrAP began as a handful of
classes created to  automatically  search  these  large trajectories  for  frames  expressing
desired  properties.  However  as  the  scope  of  the  study  increased,  so  too  did  the
capabilities of StrAP. To date StrAP possesses the following features:
35
• Fusing two separate VMD outputs into a single input file
◦ Using VMD frame lists and variable values are produced for each of the two
marked variables in a trajectory.  The lists must  then be concatenated into a
single  file  with  the  two  datasets  separated  by  a  blank  line  prior  to  StrAP
execution. StrAP then reads each line of the file transferring the contents into a
String array. Once the second dataset is encountered StrAP then cross checks
the  frame  numbers  with  the  first  dataset  already  present  in  the  array  and
incorporates  the  second  dataset's  variable  value  into  the  array  row  of  the
appropriate frame.
• Identifying trajectory frames expressing a specific dihedral angle or a pair of
specific dihedrals (this feature is not limited to dihedrals and could be used to
search for any kind of value that varies between frames, for example bond
lengths)
◦ Taking in the fused (or a singular unfused list  in the case of primary alcohol
analyses) frame list StrAP rounds the angles in the list to whole numbers and
then  compares  the  first  angle  with  the  user  defined  desired  angle.  When a
match is found a check on the second user defined angle is performed. If  a
match  on  the  second  angle  is  encountered  then  the  corresponding  frame
number is outputted and the system continues to iterate through the input file.
• Location of minima in FESs
◦ Taking in a PMF as input StrAP iterates through each line of the PMF looking for
the lowest energy value. When a value lower than its currently recorded lowest
value  is  encountered  that  value  is  stored  as  the  lowest  energy value.  This
continues until StrAP reaches the end of the file.
• Identification of minimum energy paths through FESs
◦ StrAP  iterates  through  the  PMF  file  in  2.5,  Ψ increments/bins.  For  each
increment it iterates through all corresponding  Φ values looking for the lowest
energy  value.  Each  energy  value  is  compared  against  the  recorded  lowest
energy value for that  Ψ bin. If a lower energy value is encountered it replaces
the previous lowest energy value. This continues until all  Φ values have been
iterated through at which point StrAP records the details of that lowest energy
point in an output file and moves on to the next Ψ increment. Once the final Ψ
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increment is processed the resulting output file contains the coordinates of the
lowest energy points of every Ψ increment.
• Calculation  of  changes  in  free  energy  values  between  minimum  and
maximum values given a specified range of dihedral angles
◦ Given user defined Φ and Ψ ranges and a PMF file StrAP iterates through all Φ
and  Ψ coordinates  within  the  range isolating  the  lowest  and highest  energy
values. Once StrAP has iterated through the all coordinates within the range it
outputs  the  highest  and  lowest  energy  values  and  the  difference  in  energy
between the two.
• Calculation of frequency and probability of occurrence figures for any value
that varies from frame to frame within a trajectory.
◦ StrAP creates an array in which the bins for Φ and Ψ angles and the amount of
times each of those angle combinations are encountered are stored. Given a
StrAP fused frame list as input, StrAP iterates through the list matching the  Φ
and Ψ angles in the list to entries in the array and incrementing the occurrence
of that Φ/Ψ coordinate combination by 1. Once the final value on the input list
has been processed the contents of the array are outputted to a file allowing for
further analysis using graphing programs.
As a further aid for simplifying analysis, a Tcl script named extractFrames116 was written by
the author for use within VMD. It extracts shorter, more usable trajectories from the original
1.5 million frame trajectory using StrAP's list of identified frames. The extractFrames script
makes use of the catdcd executable written by Justin Gullingsrud and distributed under the
University of Illinois Open Source License 117.
In  combination  extractFrames  and  StrAP  proved  invaluable  in  the  analysis  of  large
simulation outputs.
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Chapter 6: Results and Discussion
In this investigation first the results obtained for both the G12R and G13R disaccharides
will be  used to compare the CHARMM and GLYCAM force fields. The G12R and G13R
disaccharides will  then be compared directly.  Finally,  6-unit  polysaccharides assembled
using the minimum energy conformations of the 19A and 19F component disaccharides
will be compared in order to investigate the effect the G12R to G13R linkage shift has on
serogroup 19 CPS conformations.
The variation between the S. pneumoniae 19F and 19A serotypes is demonstrated by two
key disaccharides:  G12R and G13R (Figure  6.1).  An investigation  into  the  effects  the
shifting  of  the  glycosidic  bond  from  a  1-2  to  a  1-3  conformation  on  the  favourable
conformations  of  the  19A  and  19F  polysaccharides  could  aid  in  future  vaccine
development.
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Figure 6.1. G12R (α-D-Glucose-(1-2)-α-L-Rhamnose) (left) and G13R (α-D-Glucose-(1-3)-α-L-
Rhamnose) (right) disaccharides
The chief determinants of disaccharide conformations are the Φ and Ψ torsion angles for
the glycosidic bond between residues (Figure 6.1). As these disaccharides are the key
point of difference between 19A and 19F, a detailed analysis is a logical starting point.
6.1. Force Field Comparisons
As MD force fields have in the past yielded some disparate results when investigating
disaccharides13, we compare the CHARMM and GLYCAM force fields. G12R and G13R
were simulated using both force fields and the results are compared to determine whether
or not any major differences could be observed in aspects such as overall FES, energy
minima and relative free energy values, primary alcohol behaviour and hydrogen bonding
patterns.
6.1.1. G12R (19F)
We begin with  analysis  of  the  α-D-Glucose-(1-2)-α-L-Rhamnose (G12R) disaccharide.
CHARMM and GLYCAM Metadynamics simulations produced the FESs shown in  Figure
6.2a and 6.2b, respectively.
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Figure 6.2. G12R_C (a), G12R_G (b) FESs. G12R_C (c) and G12R_G (d) unbiased scatter plots.
Isocontour lines at 1kcal/mol intervals. Minimum energy paths (e), also shown in (a) and (b).
Minima/Barriers (Φ; Ψ; ΔG(kcal/mol))
A B C X Y
CHARMM -21.25°; 33.75°; 0.0 -41.25; -136.25; 2.08 63.75°; 63.75°; 5.87 -33.75°; 113.75°; 8.54 -
GLYCAM -36.25°; 41.25°; 0.0 -13.75°; -161.25°; 1.48 73.75°; 56.25°; 2.61 -51.25°; 126.25°; 6.86 -38.75°; -118.75°; 4.72
MM24 -34°; -35°; 0.0 - - - -
MM+45 -35°; -38°; 0.0 - - - -
Table 6.1. G12R minima and barrier torsion angles
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Figure 6.3. G12R_C (a, b and c) and G12R_G (d, e and f) minima. The red lines are hydrogen bonds.
With extensive favourable areas at or below 4kcal/mol the G12R FESs (Figure 6.2) for the
CHARMM (left column) and GLYCAM (right column) force fields, both predict a flexible
dimer. The force fields also agree on the general location of the G12R global minimum
energy conformation in the central well (A) (Φ, Ψ = -21.25°, 33.75° under CHARMM and
-36.25°;  41.25°  under  GLYCAM (Table  6.1)).  Under  both  force  fields  this  minimum is
characterised by minimal  steric strain,  a  wealth of  intraresidue hydrogen bonds and a
stabilising  O3-O'5  interresidue hydrogen bond (Figure 6.3).  While  hydrogen bonds are
believed to play a role in structural stabilisation of carbohydrates5, their effectiveness is
likely to decrease in an aqueous environment118. The global minima are in disagreement
with previous global minima as determined using the MM2 (Φ, Ψ = -34°, -35°)4 and MM+
(Φ, Ψ =  -35°, -38°)45 force fields both of which favoured the negative  Ψ region of the A
well.
The anti-Ψ region of the G12R FES (B in Figure 6.2) exhibits the major difference between
the CHARMM and GLYCAM force fields'  G12R predictions.  Under  GLYCAM a distinct
energy well is present with a secondary minimum B (Φ, Ψ = -13.75°, 41.25° (Table 6.1)).
Under CHARMM wells A and B are merged, with well A forming a long valley extending
into the B region (though not as far as GLYCAM's B well which extends into positive-Ψ).
This results in the lack of a Y barrier and no distinct B well. Instead a conformation of local
low energy is observed towards the end of the valley (Φ, Ψ =  -41.25°, -136.25° (Table
6.1)). Under GLYCAM aliphatic hydrogens carry a net charge of 0, while under CHARMM
a charge of +0.09 is used10,119. This may explain the discrepancies. Conformations in the Y
region  bring  H1 and  O'5,  and  H'1 and  O5  within  3Å  of  one  another  (Figure  6.4).
CHARMM's aliphatic charges may make these pairwise interactions stronger, lowering the
energy of Y region conformations. Conversely the close quarters between the rhamnose
and  glucose  residues  in  the  B  region  brings  aliphatic  hydrogens  into  close  proximity
(Figure 6.3). Resulting H'1-H4 and H'5-H1 pairwise interactions are likely stronger under
CHARMM, increasing the energy of the B region conformations. A more comprehensive
investigation is required.
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A tertiary minimum C (Φ, Ψ  = 63.75°, 63.75° and 73.75°, 56.25° under CHARMM and
GLYCAM respectively (Table 6.1)) was identified by both force fields. Well C is of far lower
energy  under  GLYCAM  (2.61kcal/mol)  than  under  CHARMM  (5.87kcal/mol)  and  is
characterised by an O3-O'2 interresidue hydrogen bond under both force fields (Figure
6.3).
The unbiased 100ns simulation scatter plot superimposed onto the FESs show that barrier
X (ΔG = 8.54kcal/mol under CHARMM and ΔG = 6.86kcal/mol under GLYCAM (Table 6.1))
is too high in energy to be explored in either force field (Figure 6.2c and d). As expected
with  the lower  energy of  the region under  GLYCAM, the C well  shows more frequent
occupation under  GLYCAM than CHARMM. The effect  of  the differences between the
force fields' A and B regions is highlighted. The CHARMM FES shows heavy occupation of
the extended A well  while GLYCAM shows occupation of the A and B wells with slight
occupation of the Y region indicating that it is the path of transition. The path of minimum
energy (Figure 6.2e) further highlights the long CHARMM valley with absent Y peak.
We  now  move  on  to  an  analysis  of  G12R  primary  alcohol  behaviour.  CHARMM
conformations corresponding  to  GLYCAM's  global  minimum (Φ, Ψ =  -36.25°,  41.25°),
involve  close proximity between O3 and O'5.  The O3-O'5 interresidue hydrogen bond
persists (Figure 6.5). However, when in the g+ conformation, the glucose residue's primary
alcohol group approaches the O3-O'5 bond, this appears to result in a shift in the relative
orientations of O3 and O'2 creating a pair of potential hydrogen bonds: O3-O'5 and O3-O'6
(Figure 6.5d). At ~113° and ~144° respectively, both of these bonds are further from ideal
than the original O3-O'5 hydrogen bond seen in the G12R_C minimum (angle, distance =
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Figure 6.4. G12R Y region conformation (Φ, Ψ = -44°, -116°)
173.22°, 2.8Å). This shift is not observed to occur on the same scale at Φ;  Ψ = -21.25°;
33.75°.  It  is  possible  that  CHARMM models the single hydrogen bond prevalent  in  its
minimum conformation as more favourable than the O3-O'5 and O3-O'6 pair resulting a
shifting of the global minimum coordinates.
Under GLYCAM the G12R disaccharide appears to not experience the paired interaction
at  Φ, Ψ =  -36.25°,  41.25° on the scale seen in  the CHARMM force field.  Where the
interaction would occur under CHARMM, the hydroxyls are instead orientated to allow a
single O3-O'6 bond without the intermediate orientations seen under CHARMM.
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Figure 6.5. G12R_C Conformations showing the interference by O'6 with the O3-O'5 hydrogen bond. (a): no
disruption (Φ, Ψ = -21.25°; 33.75°). (b): ineffective disruption (Φ, Ψ = -21.25°; 33.75°). (c): no disruption (Φ,
Ψ = -36.25°, 41.25°). (d): effective disruption (Φ, Ψ = -36.25°, 41.25°).  The red lines indicate hydrogen
bonds.
It  is  expected  that  the  glucose  primary alcohol  group  will  tend  to  favour  3  traditional
conformations with respect to the O5-C5-C6-O6 ω dihedral angle in order to reduce steric
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Figure 6.6. Probability of occurrence of G12R and Glc primary alcohol O5-C4-C6-O6 ω dihedral angles
strain. These conformations are trans (ω = 180), gauche+ (g+) (ω = 60) and gauche- (g-) (ω
= -60). As can be seen from Figure 6.6, G12R is no exception, with 3 distinct peaks around
ω = 180, ω = 60 and ω = -60 for both force fields. 
Conformation (ω; probability)
Unbiased Simulations
trans gauche+ gauche-
Glc_C 172°; 0.02654 62°; 0.0008 -71°; 0.01218
Glc_G 173°; 0.00901 58°; 0.00702 -66°; 0.01794
G12R_C 171°; 0.02383 63°; 0.00389 -69°; 0.01032
G12R_G 177°; 0.02845 58°; 0.00362 -65°; 0.00377
Biased Simulations
trans gauche+ gauche-
G12R_C 170°; 0.01833 59°; 0.00647 -68°; 0.01025
G12R_G 175°; 0.01867 60°; 0.00542 -65°; 0.00914
Table 6.2. Peak conformation probabilities of the O'5-C'5-C'6-O'6 ω dihedral angle for the unbiased Glc,
biased G12R and unbiased G12R simulations
Table 6.2 shows the highest values of each peak seen in Figure 6.6. With the exception of
glucose in isolation, in which GLYCAM shows similar affinity for all conformations, both
force  fields  favour  the  trans  conformation  for  G12R.  The  g -  conformation  occurs  less
frequently than trans, often with less than half the probability of occurrence with the least
popular being g+. In CHARMM glucose in isolation heavily favours the trans conformation.
The heavy favouring of the trans conformation does not fit with experimental evidence and
has been addressed in previous work by Kuttel et al. through the CSFF20. Considering the
attention given to CHARMM parametrisation for solution, the favouring of trans may be
lessened in an aqueous environment.
The orientation of the primary alcohol group affects both the O'4-O'6 intraresidue and O3-
O'6 interresidue hydrogen bonds: in g- neither bond is possible; in g+, the O'4-O'6 bond is
not possible but the O3-O'6 bond is; in trans conformation the O'4-O6 bond is possible but
the O3-O'6 is not (Figure 6.7). The lack of a strong intraresidue O'4-O'6 hydrogen bond
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may account  for  the  lack  of  gauche favourability  while  the  additional  presence of  the
seemingly unfavourable O3-O'6 interaction in the g+ conformation could explain its further
decreased popularity. Conversely the presence of the O4-O'6 bond and the absence of
O3-O'6 interaction may address the favouring of the trans conformation.
6.1.2. G13R (19A)
The investigation moves now to a comparative analysis of CHARMM and GLYCAM results
for  the  α-D-Glucose-(1-3)-α-L-Rhamnose  (G13R)  disaccharide.  As  with  G12R,  the
investigation begins with FESs generated using the Φ and Ψ torsion angles of the G13R
glycosidic linkage as collective variables in a Metadynamics sampling technique (Figure
6.8).  Φ and  Ψ torsion  angle  coordinates  visited  during  an  unbiased  simulation  were
collated into a scatter plot and superimposed over the FESs (Figure 6.8c and  6.8d) in
order to provide a general overview of the nature of the G13R disaccharide.
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Figure 6.7. G12R_C primary alcohol in trans (a), g+ (b) and g- (c). The red lines indicate hydrogen bonds
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Figure 6.8. G13R_C (a), G13R_G (b) FESs. G13R_C (c) and G13R_G (d) unbiased scatter plots.
Isocontour lines at 1kcal/mol intervals. Minimum energy paths (e), also shown in (a) and (b).
Minima/Barriers (Φ; Ψ; ΔG(kcal/mol))
A B C X Y
CHARMM
-33.75°; -38.75°; 0.0 -28.75°; 171.25°; 2.18 68.75°; 56.25°; 6.67 -58.75°; 118.75°; 8.16 -51.25°; -133.75°; 6.68
-28.75°; 43.75°; 1.31
GLYCAM
-13.75°; -53.75°; 0.0 -11.25°; 171.25°; 0.78 66.25°; 51.25°; 4.18 -53.75°; 108.75°; 7.53 -56.25°; -118.75°; 7.84
36.25°; 16.25°; 0.32
28.75; 6.25; 1.35
MM24 -35; -38; 0.0 -28; -175; 4.3 -
Table 6.3. G13R minima and barrier torsion angles
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Figure 6.9. G13R minima conformations. The red lines indicate hydrogen bonds
The  G13R  FESs  (Figure  6.8)  for  CHARMM  (left)  and  GLYCAM  (right),  are  more  in
agreement than was the case in G12R. In both force fields the central A well contains the
global minimum (Φ, Ψ = -33.75°, -38.75° for CHARMM and  Φ, Ψ = -13.75°, -53.75° for
GLYCAM (Table 6.3)) characterised by an O2-O'2 interresidue hydrogen bond (Figure 6.9).
Both force fields show two regions of low energy conformations, a favoured negative-Ψ
region containing the global minimum and a secondary positive-Ψ region. The A well is
broader with lower energy states than seen under CHARMM: GLYCAM exhibits a less
favoured tertiary positive-Φ region (Φ, Ψ = 28.75°, 6.25° (Table 6.3)) absent in CHARMM
and a secondary local  minimum of  lower energy than that  of  CHARMM (Φ, Ψ,  ΔG =
-28.75°, 43.75°, 1.31kcal/mol for CHARMM and Φ, Ψ, ΔG = -36.25°, 16.25°, 0.32kcal/mol
for GLYCAM (Table 6.3)). Previous HSEA and MM2 force field calculations presented a
global minimum of  Φ, Ψ  = -35°, -38°4 which, while in close agreement with both force
fields, is particularly close to the CHARMM global minimum.
Unlike in  G12R, both force fields predict  a distinct  well  in  region B containing a local
minimum. Located at Φ, Ψ = -28.75°, 171.25°, for CHARMM and Φ, Ψ = -11.25°, 171.25°,
for GLYCAM (Table 6.3), the minimum is of considerably lower energy under GLYCAM
(0.78kcal/mol  under  GLYCAM  and  2.18kcal/mol  under  CHARMM  (Table  6.3)).  The
previous MM2 investigation identified a tertiary minimum in the B region at  Φ, Ψ = -28°,
-175°, though at 4.3kcal/mol this minimum is of significantly higher energy4.
The well in region C is similarly positioned in both CHARMM (Φ, Ψ = 68.75°, 56.25°) and
GLYCAM (Φ, Ψ = 66.25°, 51.25°) (Figure 6.8 and Table 6.3). Characterised by an O2-O'2
hydrogen bond (Figure 6.9), GLYCAM (4.18kcal/mol) predicts a lower energy minimum
than that of CHARMM (6.67kcal/mol) (Table 6.3).
Under GLYCAM the Y (7.84kcal/mol) and X (7.53kcal/mol) barriers have similar heights
(Figure 6.8 and Table 6.3) while under CHARMM the Y barrier (6.68kcal/mol) is lower than
the X barrier (8.16kcal/mol). The higher Y values make transition more difficult and, as
seen in the scatter plots of the unbiased 100ns simulations (Figure 6.8c and d), transition
from well A to B occurs only under CHARMM, though the sparse population of CHARMM's
Y region suggests that transition is less frequent than that observed for G12R. GLYCAM
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well  A's  tertiary  energy  well  is  more  densely  populated  than  the  equivalent  area  in
CHARMM while well C remains unexplored under both force fields (Figure 6.3).
The behaviour of the primary alcohol group in G13R is now further investigated.  Figure
6.10 and Table 6.4 document the overall probability of occurrence of primary alcohol group
O5-C5-C6-O6 ω torsion angles in the biased and unbiased G13R MD simulations of both
force fields.
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Figure 6.10. Probability of occurrence of G13R and Glc primary alcohol O5-C4-C6-O6 ω dihedral angles
Conformation (ω; frequency)
Unbiased Simulations
trans gauche+ gauche-
Glc_C 172°; 0.02654 62°; 0.0008 -71°; 0.01218
Glc_G 173°; 0.00901 58°; 0.00702 -66°; 0.01794
G13R_C 173°; 0.02657 60°; 0.00347 -68°; 0.00903
G13R_G 176°; 0.03271 63°; 0.00047 -68°; 0.00379
Biased Simulations
trans gauche+ gauche-
G13R_C 171°; 0.01805 61°; 0.00601 -69°; 0.01088
G13R_G 177°; 0.02112 60°; 0.00278 -66°; 0.00979
Table 6.4. Peak conformation probabilities of the O'5-C'5-C'6-O'6 ω dihedral angle for the unbiased Glc,
biased G13R and unbiased G13R simulations
In G13R the trans, g+ and g- peaks are at 171°, 61° and -69° under CHARMM and 177°,
60° and -66° in  GLYCAM respectively (Table 6.4).  As in  G12R,  with  the exception  of
GLYCAM's 100ns glucose simulation, both force fields favour the trans conformation. The
lower g- probability seen in unbiased G13R_G simulations occurs only in that simulation
and may be a result of the largely unexplored FES stemming from the lack of transition
from well A to well B (Figure 6.8d). There is also a noticeable difference in the probability of
occurrence of the g+ conformation between force fields. GLYCAM produces g+ frequencies
significantly lower than those of CHARMM in all simulations (Table 6.4).
The G13R primary alcohol group's conformation influences both the O4-O'6 and O'4-O'6
intraresidue hydrogen bond: in trans the intraresidue bond is retained but the interresidue
bond is not; in g+ the interresidue bond is possible but the intraresidue bond is not; in g -
neither  bond  can  be  formed (Figure  6.11).  The  favouring  of  trans  may be  due  to  its
orientation allowing for the formation of the intraresidue O'4-O'6 hydrogen bond. As the
impact of hydrogen bonds has been known to change in aqueous solutions118 it is possible
that the favouring of trans is a phenomenon isolated to vacuum conditions.
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Despite some discrepancies, in both the G12R and G13R the FESs obtained with both
force fields are in close agreement in terms of location of minimum energy conformations.
GLYCAM consistently predicts broader energy wells with local minima of lower values than
those of CHARMM. It can therefore be said that GLYCAM predicts an altogether more
flexible disaccharide than CHARMM with less potential for well transition.
6.2. Linkage Comparison
G12R and G13R differences have implications for the conformation of the serogroup 19
trisaccharide repeating units and the CPSs those repeating units form. A small change in
the  most  favoured  glycosidic  Φ and Ψ  dihedral  angles  could  result  in  considerable
conformational differences when compounded over a chain of repeating units.
The MM2 study predicted similar G12R and G13R FESs. With its single centralised well of
low energy,  the  FESs described disaccharides of  limited  flexibility4.  The application  of
modern day force fields orientated specifically towards the simulation of carbohydrates has
improved upon this view. The CHARMM and GLYCAM simulations have predicted more
flexible disaccharides in both G12R and G13R. While both G12R and G13R have similar
Φ and Ψ ranges (Figure 6.12),  G12R appears to be the more flexible disaccharide with
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Figure 6.11. G13R_C primary alcohol in trans (a), g+ (b) and g- (c) conformations. The red lines indicate
hydrogen bonds
frequently explored anti-Ψ conformations (Figure 6.2c and d). Both force fields show a rise
in  X and Y barrier  heights  for  G13R over  those of  G12R impeding rotation  to  anti-Ψ
conformations in G13R (Figure 6.13). This is more noticeable under CHARM where G12R
lacks a distinct Y barrier and G13R possesses a sizeable 6.68kcal/mol Y barrier. Under
GLYCAM the trend is less pronounced with the Y barrier rising from 4.72kcal/mol in G12R
to  7.84kcal/mol  in  G13R.  Further  reinforcing  this  observation  is  the  seemingly  rare
transition between wells under CHARMM and the complete absence of transition under
GLYCAM in G13R (Figure 6.8c and d).
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Figure 6.12. FESs of G12R_C (a), G12R_G (c), G13R_C (b) and G13R_G (d). The isocontour lines are
1kcal/mol increments with a 15kcal/mol cutoff
The FESs contain some differences, the most noticeable being the merging of G12R wells
A and B under CHARMM while G13R exhibits a distinct secondary energy well B under
both force fields (Figure 6.12). In a similar manner the global minima torsion angles differ
dramatically in response to the (1-2) to (1-3) glycosidic shift. While  Φ angles show little
change the Ψ angles shift by 72.5° under CHARMM and a remarkable 95° under GLYCAM
(Table 6.6).
Force Field G12R Minimum (Φ; Ψ) G13R Minimum (Φ; Ψ) Degree Shift (Φ; Ψ)
CHARMM -21.25°; 33.75° -33.75°; -38.75° 12.5°; 72.5°
GLYCAM -36.25°; 41.25° -13.75°; -53.75° 22.5°; 95°
Table 6.5.Degree shift in G12R and G13R global minima
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Figure 6.13. Minimum energy paths for G12R and G13R. Key wells and peaks from Figure 6.12 are
labelled
6.3. Oligosaccharide Extensions
The oligosaccharide  repeating  unit  chains  depicted  in  this  section  are  limited  in  their
application due to the lack of availability of reliable phosphodiester bond parameters for
both  CHARMM and  GLYCAM.  While  potential  conformational  impacts  are  highlighted,
inferences onto actual in vivo 19A and 19F CPSs are not necessarily reliable.
Extension Force Field Minimum EnergyConformation Linkage Dihedral (Φ; Ψ)
M14G13R_CA6 CHARMM A G13R -34°; -39°
M14G13R_GA6 GLYCAM A G13R -14°; -54°
M14G12R_CA6 CHARMM A G12R -21°; 34°
M14G12R_CB6 CHARMM B G12R -41°; -136°
M14G12R_GA6 GLYCAM A G12R -36°; 41°
M14G12R_GB6 GLYCAM B G12R -14°; -161°
ALL GLYCAM A M14G 49°; -14°
ALL Phosphodiester 0°; 0°
Table 6.6. Oligosaccharide extension designations
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Overall  the  extensions  utilising  G12R or  G13R global  minimum energy conformations
(M14G13R_CA6, M14G13R_GA6, M14G12R_CA6 and M14G12R_GA6 (Table 6.6)) show
few structural discrepancies (Figure 6.14). While the M14G12R_CA6 helix is slightly more
tightly coiled, all four extensions exhibit a flat extended helical structure regardless of force
field or component disaccharides utilised. In the extensions utilising G12R or G13R global
minimum energy conformations,  the residues and the phosphate group remain readily
accessible for antibody binding. The minor conformational variations are therefore unlikely
to explain the lack of 19F to 19A cross protection.
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Figure 6.14. 6-unit oligosaccharide extension structures
The  extensions  utilising  G12R  B  minimum  energy  conformations  under  CHARMM
(M14G12R_CB6) and GLYCAM (M14G12R_GB6) differ structurally from the global minima
extensions. The B minima extensions both exhibit tightly coiled helices. The tightly coiled
nature of these oligosaccharides may occlude residues and phosphate groups therefore
making antibody access difficult.
These conformations demonstrate that, given similarly arranged phosphate groups, the
differences in global minimum energy conformations between the G12R and G13R are
unlikely to impact greatly on the conformation of 19A and 19F polysaccharide repeating
unit  chains.  The  B  minima  however  produce  structures  that  could  perceivably  cause
difficulty with  respect  to  vaccine efficacy.  The reasons for  the lack of  cross protection
observed between 19A and 19F in vaccines such as PCV7 are not readily apparent.
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Chapter 7: Conclusions and Future Work
This work stands as both a comparison of the CHARMM and GLYCAM carbohydrate force
fields and an initial computational investigation into the S. pneumoniae serotype 19A and 
19F CPSs.
While  there  were  discrepancies  between  the  CHARMM  and  GLYCAM  conformations,
overall their predictions were in agreement. Both force fields presented minimum energy
conformations  in  close  agreement  with  one  another  even  when  extended  to  form
oligosaccharides. GLYCAM consistently described a more flexible glycosidic linkage than
CHARMM, with broader secondary minima of lower energy. CHARMM also predicted a far
more readily accessible, albeit narrower, B region than GLYCAM. While the exact causes
are  difficult  to  isolate,  these  discrepancies  could  be  explained  by  GLYCAM's  lack  of
aliphatic hydrogen charges which are present in CHARMM.
The G12R and G13R linkages differed considerably. The G12R linkage was predicted by
both force fields to have greater flexibility than that observed in G13R. Minimum energy
conformations and the ability to transition between them also differed significantly.  The
difference was most pronounced under CHARMM. Both G12R and G13R global minima
oligosaccharide extensions exhibited flat extended helical structures. The slight structural
variations observed in the oligosaccharide extensions do not explain the lack of cross-
protection observed for 19A by 19F vaccine conjugates.
This study confirms through both the CHARMM and GLYCAM force fields, that there are
differences  between  the  minimum  energy  conformations  of  the  G12R  and  G13R
disaccharides. While these differences could account for the lack of 19F vaccine conjugate
cross protection for 19A, more work will need to be performed to confirm this. Future work
simulating  full  19A  and  19F  CPSs  in  solution  using  parameter  sets  including
phosphodiester  bond  parameters  allowing  for  the  consideration  of  more  extensive
interresidue interactions would be beneficial. The addition of other dominant carbohydrate
force  fields  in  addition  to  CHARMM  and  GLYCAM  (such  as  GROMOS),  along  with
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experimental approaches such as NMR spectroscopy investigations into CPS structures
could serve to validate further research. This investigation serves as an initial step into a
multifaceted topic that could easily form the basis for a larger and more comprehensive
study.
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Chapter 9: Appendices
Appendix A: NAMD Configuration Files
1. G12R_C Unbiased Simulation Configuration File
# Written by: M. Kuttel November 2011 
# Modified by: M. Gordon February 2012 
# NAMD Config file for unbiased run of aDGlc-a12-aLRha bond of S. pneumoniae serogroup 19 carbohydrate repeating unit 
# input 
coordinates             ./structures/aDGlc-a12-aLRha.pdb 
structure               ./structures/aDGlc-a12-aLRha.psf 
#used for restarting simulation using minimisation output files 
bincoordinates ./minimisation/output/aDGlc-a12-aLRha.coor 
binvelocities ./minimisation/output/aDGlc-a12-aLRha.vel 
extendedSystem ./minimisation/output/aDGlc-a12-aLRha.xsc 
parameters              ./forcefields/toppar_carb_apr12/par_all36_carb(marcEdit).prm 
paratypecharmm          on 
# output 
set output              ./output/aDGlc-a12-aLRha 
outputname              $output 
DCDfile $output.dcd 
#by default it should be binary output 
binaryoutput            yes 
outputEnergies 100 
dcdfreq    1000 
#fixedAtoms              off 
# Basic dynamics 
exclude                 scaled1-4 
1-4scaling              1 
COMmotion               no 
dielectric              1.0 
# Simulation space partitioning 
switching               on 
switchdist              12 
cutoff                  15 
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pairlistdist            18 
# Temperature control 
reassignFreq 1000 
reassignTemp 25 
reassignIncr 25 
reassignHold 300 
# run duration
run 100000000
2. G12R_C Biased Simulation Configuration File
# Written by: M. Kuttel November 2011 
# Modified by: M. Gordon February 2012 
# NAMD Config file for Metadynamics run of aDGlc-a12-aLRha bond of S. pneumoniae serogroup 19 carbohydrate repeating unit 
# input 
coordinates             ./structures/aDGlc-a12-aLRha.pdb 
structure               ./structures/aDGlc-a12-aLRha.psf 
#used for restarting simulation using minimisation output files 
bincoordinates ./minimisation/output/aDGlc-a12-aLRha.coor 
binvelocities ./minimisation/output/aDGlc-a12-aLRha.vel 
extendedSystem ./minimisation/output/aDGlc-a12-aLRha.xsc 
parameters              ./forcefields/toppar_carb_apr12/par_all36_carb(marcEdit).prm 
paratypecharmm          on 
# output 
set output              ./output/aDGlc-a12-aLRha 
outputname              $output 
DCDfile $output.dcd 
binaryoutput            yes 
outputEnergies 100 
dcdfreq    1000 
#fixedAtoms              off 
# Basic dynamics 
exclude                 scaled1-4 
1-4scaling              1 
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COMmotion               no 
dielectric              1.0 
# Simulation space partitioning 
switching               on 
switchdist              12 
cutoff                  15 
pairlistdist            18 
# Temperature control 
reassignFreq 1000 
reassignTemp 25 
reassignIncr 25 
reassignHold 300 
# NAMD colvars module 
colvars on 
colvarsConfig colvars.txt 
# run duration 
run 1500000000
Appendix B: NAMD Colvars Module Configuration Files
1. G12R_C
colvarsTrajFrequency 1000  
#NB - change this when change  targetNumSteps 
colvarsTrajAppend off 
#when running consecutive simulations with the same outputName 
#enable this option to preserve the previous contents of the trajectory file.
colvar { 
   name Phi 
   width 2.5 
   dihedral { 
      group1 { 
         atomnumbers { 24 } 
      } 
      group2 { 
         atomnumbers { 23 } 
      } 
      group3 { 
         atomnumbers { 2 } 
      } 
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      group4 { 
         atomnumbers { 1 } 
      } 
   } 
    lowerBoundary -180 
   upperBoundary 180 
} 
 
colvar { 
   name Psi 
   width 2.5 
   dihedral { 
      group1 { 
         atomnumbers { 10 } 
      } 
      group2 { 
         atomnumbers { 1 } 
      } 
      group3 { 
         atomnumbers { 2 } 
      } 
      group4 { 
         atomnumbers { 23 } 
      } 
   } 
 lowerBoundary -180 
   upperBoundary 180 
} 
Metadynamics { 
name metaPhiPsi 
colvars Phi Psi 
hillWeight 0.05 #choose carefully - 0.01 seemed too small, 0.5 seemed to cause instability 
dumpFreeEnergyFile yes 
}
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